Electra Therapeutics priced an upsized $350 million IPO, a significant cash infusion aimed at advancing its pan-SIRP monoclonal antibody ipsoprubart in secondary hemophagocytic lymphohistiocytosis (sHLH). The listing underscores continued investor appetite for late-stage clinical programs focused on inflammatory drivers and urgent unmet need settings.